Since ATOX1 is a copper chaperone protein involved in breast cancer cell migration and breast cancer progression [5,6], we here evaluated ATOX1 as a predictive biomarker for the benefit of TM treatment using cancer tissue material and follow-up data from the breast cancer patients in the phase II clinical trial [9]. Here, ATOX1 is linked to breast cancer.